FAG
BEAM icon

Fortitude Advisory Group’s Beam Therapeutics BEAM Stock Holding History

Fortitude Advisory Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$6K – 316
2022
Q1 		$6K Hold
100
– – ﹤0.01% 1124
2021
Q4 		$8K Buy
+100
New +$8.56K ﹤0.01% 1084

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fortitude Advisory Group's BEAM Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 100 shares — an estimated $6K sold.

Fortitude Advisory Group first reported a position in BEAM in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q4 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • Fortitude Advisory Group reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 100 Beam Therapeutics shares in Q2 2022, an estimated $6K.
  • Fortitude Advisory Group first reported a position in Beam Therapeutics in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's Beam Therapeutics position peaked at $8K in Q4 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.